Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
Date:11/1/2011

2010, net loss included non-cash, stock-based compensation expense of $1.3 million and $4.0 million, respectively.Cash and Investments:  As of September 30, 2011, Lexicon had $144.2 million in cash and investments, as compared to $164.8 million as of June 30, 2011 and $211.1 million as of December 31, 2010.  

Lexicon Conference Call:Lexicon management will hold a conference call to discuss its clinical development progress and financial results for the third quarter of 2011 at 11:00 a.m. Eastern Time today.  The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international).  The conference ID for all callers is 20122666.  Investors can access a live webcast of the call at www.lexpharma.com.  An archived version of the webcast will be available on Lexicon's corporate website through November 29, 2011.

About LexiconLexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor StatementThis press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031, LX1032, LX1033, LX2931, and LX4211, including characterizations of the results of and projected timing of clinical trials of such
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
2. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
3. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
4. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
5. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
6. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
7. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
9. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
11. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  Amgen (NASDAQ: AMGN ) ... year 2014 financial results on Tuesday, Jan. 27, 2015, after the ... by a conference call with the investment community at 2 p.m. ... A. Bradway , chairman and chief executive officer, and other members ...
(Date:1/22/2015)... Calif. , Jan. 22, 2015 Increasing sophistication ... continued consolidation of localization purchasing in 2015, says ... According to a recent study by market research firm ... a single-source solution for their translation and localization needs. ...
(Date:1/22/2015)... ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the addition of ... by End User - Global Forecast to 2019" report ... market is valued at $1,228.58 million in 2014 and is ... $2,230.72 million by 2019. Allergy diagnostics is used to determine ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... BELGRADE, Mont., Nov. 15, 2010 Bacterin International Holdings, ... BIHI ), a developer of anti-infective coatings for ... financial results for its third quarter ended September 30, ... the reverse merger transaction reported in the Company,s Form ...
... Corporation (Nasdaq: PRXL ), a leading global biopharmaceutical ... 2010 Scrip Award for "Clinical Research Team of ... at the sixth annual Scrip Awards ceremony, hosted ... information service for the global pharmaceutical industry, on November 4, ...
Cached Medicine Technology:Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results 2Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results 3Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results 4Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results 5Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results 6Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results 7Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results 8Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results 9PAREXEL Wins Clinical Research Team of the Year Scrip Award 2PAREXEL Wins Clinical Research Team of the Year Scrip Award 3PAREXEL Wins Clinical Research Team of the Year Scrip Award 4PAREXEL Wins Clinical Research Team of the Year Scrip Award 5
(Date:1/22/2015)... 22, 2015 Autocarinsurancebest.com has released a new ... commercial auto insurance policy . , Auto insurance quotes ... It is no longer necessary to call an agent or ... available online on a single website: http://autocarinsurancebest.com/ . , ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... Four years since the release of their debut ... the marriage of Avasa & Matthew Love – the duo are ... for release through White Swan Records on February 24, 2015. , ... sacred path available to all of us to walk out of ...
(Date:1/22/2015)... January 22, 2015 JJsHouse.com is a famous ... Today, the business announces its latest collection of wedding ... “The most important issue is the wedding dress on your ... in a woman’s life. Every bride wants to find the ...
(Date:1/22/2015)... USA (PRWEB) January 22, 2015 State ... statewide data management system with support from GEOSYSTEMS, a ... The new solution will leverage Hexagon Geospatial’s ERDAS ... vector data as well as point clouds and documents. ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... Oct. 11 At "Managing Quality to,Drive Growth," ... LLC,s,Global Benchmarking Council (GBC), executives from 20 leading ... for quality and,growth; product innovation excellence; process simplification ... successes in integrating quality into,sales, marketing and new ...
... ALOKA Co., Ltd., a pioneer in the,development ... Masanobu Tada as President, and Carlos Faustmann as ... the company,s,wholly-owned European headquarters in Zug, Switzerland, with ... Global Marketing of the company as,general manager since ...
... YORK, Oct. 10 Molina Healthcare Inc. (NYSE: MOH ... in the S&P,SmallCap 600 after the close of trading on ... constituent LKQ Corp. (Nasdaq: LKQX ) in,a deal that ... final,approvals. Standard & Poor,s will monitor this transaction, and ...
... PORTLAND, Ore., Oct. 10 Mark Ganz, President and ... a prominent group of,thought leaders and health policy experts ... major initiative to reframe and broaden the,national dialogue on ... and beyond. The Aspen Health Stewardship Project will ...
... performed equally in high-tech tests , , WEDNESDAY, Oct. 10 ... runners should follow Prince Charming,s lead and consider a ... , Using high-tech methods, a team of Scottish scientists ... between $80 pairs of running shoes and pairs made ...
... to Protect Health Benefit, MARYSVILLE, Calif., Oct. 10 ... to announce the filing of a,formal grievance over the ... caregivers earlier this year. Because of the county,s ... residents who are elderly or have disabilities must play,a ...
Cached Medicine News:Health News:Mastering Challenges & Measuring Successes for Quality Initiatives in Sales, Marketing and Product Development 2Health News:ALOKA Appoints New Management in Europe 2Health News:Standard & Poor's Announces Change to U.S. Index 2Health News:Regence CEO to Chair National Effort Promoting Broader Health Care Stewardship 2Health News:Regence CEO to Chair National Effort Promoting Broader Health Care Stewardship 3Health News:Pricey Running Shoes Not Worth It: Study 2Health News:Pricey Running Shoes Not Worth It: Study 3Health News:Pricey Running Shoes Not Worth It: Study 4Health News:Caregivers Demand County Honor Their Contract 2
Mounted on a fully adjustable molded,headband with crown strap and comfort,cushions, the sturdy Trueview Classic is,lightweight, comfortable and durable....
Mounted on a fully adjustable molded,headband with crown strap and comfort,cushions, the sturdy Halogen III Classic is,lightweight, comfortable and durable....
Mounted on a sturdy, molded headband,the Classic has a fully adjustable,crown strap and cushioning that adds,to your comfort....
... InterGro DBM putty is a ... most trusted names in human tissue ... in bone grafting technology. InterGro ... lipid carrier (lecithin) to deliver a ...
Medicine Products: